Foundayo articles and explainers
Plain-English explainers about Foundayo (orforglipron) — the trials behind it, how it compares with other GLP-1 medicines, and where UK approval stands. Every article is information only: we do not sell medicines, recommend suppliers, or give medical advice.
If you are just getting to know Foundayo, the core pages come first: what it is, its six strengths and dose ladder, side effects, UK availability, how it was developed and the FAQ. Each article below then picks up one question and answers it in more depth.
Can Foundayo cause low blood sugar? Hypoglycaemia explained
Foundayo and low blood sugar: why the hypo risk with orforglipron alone is low, how insulin and sulfonylureas change that, NHS hypo steps and DVLA rules.
Storing Foundayo: heat, light, travel and the blister pack
Storing Foundayo tablets: the exact UK label wording on light and temperature, why the blister matters, flying, time zones, damaged packs and disposal.
Can you take Foundayo with food? What the label says
Can you take Foundayo with food? Yes. What the UK SmPC and leaflet say about meals, water, timing, nausea and storage, and how the Wegovy pill's rule differs.
Who can take Foundayo? UK eligibility explained
Who can take Foundayo in the UK: the licensed BMI thresholds, type 2 diabetes, the age limit, who should not take it, and the cautions a prescriber weighs.
Orforglipron in the UK: the approval timeline so far
Orforglipron UK approval date from the sources: MHRA licence 10 August 2026, private prescribing from 24 August 2026, NICE guidance expected 27 January 2027.
Will Foundayo be available on the NHS? What we know so far
Foundayo NHS availability as of October 2026: not on the NHS yet. How NICE's appraisal (ID6516) works, the 27 January 2027 date, and what a yes would mean.
Foundayo drug interactions: other medicines to know about
Foundayo drug interactions in the UK label: clarithromycin, rifampicin, St John's wort, simvastatin, the pill, and diabetes and blood pressure medicines.
Orforglipron vs semaglutide: how the two molecules differ
Orforglipron vs semaglutide: a small-molecule daily tablet against a peptide given weekly or as a fasting tablet — mechanism, dosing, trials and UK status.
Foundayo dosage schedule: the dose steps month by month
The Foundayo dosage schedule month by month: 0.8 mg for 30 days, then 2.5 mg and 5.5 mg, with optional steps to 17.2 mg. What the UK label says about each.
How to take Foundayo: the daily tablet with no fasting rules
How to take Foundayo (orforglipron): one tablet a day, any time, with or without food — the routine, the dose ladder, missed doses, storage and cautions.
Orforglipron Trial Results: What ATTAIN and ACHIEVE Found
Orforglipron (Foundayo) trial results in plain English: ATTAIN-1 weight loss by dose, diabetes trials, the head-to-head with oral semaglutide, side effects.
Foundayo side effects: what the UK leaflet and trials report
Foundayo (orforglipron) side effects from the UK SmPC, patient leaflet and ATTAIN trials: how common nausea is, why it eases, and which signs need help.
Foundayo vs Mounjaro: Tablet and Injection Compared
Foundayo vs Mounjaro compared in plain English: how the oral GLP-1 tablet and the weekly injection differ in mechanism, delivery and UK status.
How Orforglipron Works: The Science Behind Foundayo
A plain-English guide to how orforglipron (Foundayo) works — how this oral GLP-1 tablet mimics a gut hormone, and how it differs from injections.